Reier-Nilsen T, et al. - In children who are highly allergic to peanut, researchers have determined the feasibility of achieving a maximum maintenance dose (MMD) of 5000 mg peanut protein or, alternatively, a lower individual maintenance dose (IMD), an increase in the oral immunotherapy (OIT) dose, as well as identified adverse events (AEs), and the factors associated with achieving a maintenance dose. The TAKE-AWAY peanut OIT trial enlisted 77 children (aged 5-15 years) with a positive oral peanut challenge. Although a maintenance dose of 0.25-5 g was reached by 75.5% of children with peanut anaphylaxis, only 21.1% reached MMD. Data reported that during up-dosing, 19.4% experienced anaphylaxis. According to findings, distaste for peanuts and AEs, including the high risk of anaphylaxis, limited the probability of reaching MMD.